Abstract
In the past decade, the resurgence of immunotherapy has changed the landscape of cancer therapy. Checkpoint inhibitors targeting cytotoxic T-lymphocyte antigen-4, programmed death-1 on lymphocytes, and programmed death ligand-1 on tumors cells are currently utilized in the management of several cancers. These agents are double-edged sword with the positive effect being robust antitumor response but on the other side they can throttle up the normal immunologic homeostasis in a negative way, leading to adverse autoimmune toxicities. These adverse toxicities are frequent if patients have active autoimmune disorders. Here, we report a rare case of quiescent bullous pemphigoid which flared after initiation of pembrolizumab, a programmed death ligand-1 inhibitor.
Original language | English (US) |
---|---|
Pages (from-to) | 42-44 |
Number of pages | 3 |
Journal | Journal of Immunotherapy |
Volume | 41 |
Issue number | 1 |
DOIs | |
State | Published - 2018 |
Externally published | Yes |
Keywords
- Immunotherapy
- bullous pemphigus
- corticosteroids
- pembrolizumab
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Pharmacology
- Cancer Research